1.87
price up icon10.00%   0.17
after-market 시간 외 거래: 1.83 -0.04 -2.14%
loading
전일 마감가:
$1.70
열려 있는:
$1.74
하루 거래량:
36,418
Relative Volume:
0.54
시가총액:
$2.67M
수익:
-
순이익/손실:
$-7.98M
주가수익비율:
-0.2132
EPS:
-8.7693
순현금흐름:
$-6.49M
1주 성능:
+0.00%
1개월 성능:
-26.95%
6개월 성능:
-78.63%
1년 성능:
-89.67%
1일 변동 폭
Value
$1.6923
$1.87
1주일 범위
Value
$1.67
$1.9763
52주 변동 폭
Value
$1.54
$30.25

Adial Pharmaceuticals Inc Stock (ADIL) Company Profile

Name
명칭
Adial Pharmaceuticals Inc
Name
전화
434-422-9800
Name
주소
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Name
직원
6
Name
트위터
@AdialPharma
Name
다음 수익 날짜
2024-12-12
Name
최신 SEC 제출 서류
Name
ADIL's Discussions on Twitter

Compare ADIL vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ADIL
Adial Pharmaceuticals Inc
1.87 2.43M 0 -7.98M -6.49M -8.7693
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.05 114.72B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
737.45 78.67B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
684.50 42.38B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
311.10 41.75B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
282.72 31.33B 5.36B 287.73M 924.18M 2.5229

Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-14 개시 Rodman & Renshaw Buy
2018-10-30 개시 Maxim Group Buy
2018-10-11 개시 Dawson James Buy

Adial Pharmaceuticals Inc 주식(ADIL)의 최신 뉴스

pulisher
Mar 17, 2026

Nasdaq Moves: Whats the beta of Adial Pharmaceuticals Inc stock2026 Analyst Calls & Real-Time Volume Analysis - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 16, 2026

Revenue per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView

Mar 16, 2026
pulisher
Mar 07, 2026

Tech Rally: Whats the fair value of Adial Pharmaceuticals Inc stockPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 07, 2026

Is Adial Pharmaceuticals Inc. stock a smart buy before Fed meetingPortfolio Return Report & High Conviction Investment Ideas - Naître et grandir

Mar 07, 2026
pulisher
Mar 06, 2026

Key facts: Adial Pharmaceuticals reports $7.98M annual loss; 2025 results show regulatory progress - TradingView

Mar 06, 2026
pulisher
Mar 06, 2026

Adial Pharmaceuticals (ADIL) Enhances Financial Position and Cli - GuruFocus

Mar 06, 2026
pulisher
Mar 06, 2026

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - TradingView

Mar 06, 2026
pulisher
Mar 06, 2026

Adial Pharmaceuticals (NASDAQ: ADIL) outlines AD04 advances, Europe deal and Nasdaq win - Stock Titan

Mar 06, 2026
pulisher
Mar 06, 2026

FDA policy shift could give Adial cheaper route for alcohol-use drug - Stock Titan

Mar 06, 2026
pulisher
Mar 05, 2026

Adial Pharmaceuticals 10-K: $(7.98M) Net Loss, $(11.93) EPS; Cash into H2 2026 - TradingView

Mar 05, 2026
pulisher
Mar 04, 2026

Adial Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 04, 2026
pulisher
Mar 04, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 04, 2026
pulisher
Mar 04, 2026

ADIL SEC FilingsAdial Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Adial Pharmaceuticals signs framework deal with Molteni for Europe By Investing.com - Investing.com Canada

Mar 04, 2026
pulisher
Mar 03, 2026

Adial Pharmaceuticals (ADIL) Plans European Expansion for AD04 w - GuruFocus

Mar 03, 2026
pulisher
Mar 03, 2026

Adial Pharmaceuticals signs exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

Adial Pharmaceuticals signs framework deal with Molteni for Europe - Investing.com

Mar 03, 2026
pulisher
Mar 03, 2026

Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks

Mar 03, 2026
pulisher
Mar 03, 2026

Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

Adial (NASDAQ: ADIL) outlines AD04 Europe deal framework with Molteni - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Adial Pharmaceuticals, Inc. Enters into A Collaboration Framework Agreement with Molteni Farmaceutici - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million - Benzinga

Mar 03, 2026
pulisher
Mar 03, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Mar 03, 2026
pulisher
Mar 02, 2026

Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World

Mar 02, 2026
pulisher
Mar 01, 2026

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - ADVFN Ltd

Mar 01, 2026
pulisher
Feb 26, 2026

Adial Pharmaceuticals, IncWarrant (NQ: ADILW - The Chronicle-Journal

Feb 26, 2026
pulisher
Feb 26, 2026

Adial Pharmaceuticals Secures Exchange Listing Amid Regulatory Tailwinds - AD HOC NEWS

Feb 26, 2026
pulisher
Feb 26, 2026

ADIL Should I Buy - Intellectia AI

Feb 26, 2026
pulisher
Feb 26, 2026

Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 87.7% - Defense World

Feb 26, 2026
pulisher
Feb 25, 2026

ADIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 25, 2026
pulisher
Feb 25, 2026

Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - The Globe and Mail

Feb 25, 2026
pulisher
Feb 24, 2026

ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus

Feb 24, 2026
pulisher
Feb 24, 2026

Key facts: Adial Pharmaceuticals meets Nasdaq bid requirement; advances AD04 to Phase 3 trial - TradingView

Feb 24, 2026
pulisher
Feb 24, 2026

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Bitget

Feb 24, 2026
pulisher
Feb 24, 2026

Adial Pharmaceuticals regains full compliance with Nasdaq listing requirement - marketscreener.com

Feb 24, 2026
pulisher
Feb 24, 2026

Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView

Feb 24, 2026
pulisher
Feb 24, 2026

Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement - TradingView

Feb 24, 2026
pulisher
Feb 24, 2026

Adial Pharmaceuticals (ADIL) regains Nasdaq compliance, highlights AD04 Phase 3 path - Stock Titan

Feb 24, 2026
pulisher
Feb 24, 2026

Adial Pharmaceuticals eyes single pivotal trial path for AD04 - Investing.com India

Feb 24, 2026
pulisher
Feb 23, 2026

Adial Pharmaceuticals eyes single pivotal trial path for AD04 By Investing.com - Investing.com Australia

Feb 23, 2026
pulisher
Feb 23, 2026

Adial Pharmaceuticals stock rises on FDA policy shift By Investing.com - Investing.com South Africa

Feb 23, 2026
pulisher
Feb 23, 2026

Adial Pharmaceuticals stock rises on FDA policy shift - Investing.com

Feb 23, 2026
pulisher
Feb 23, 2026

Adial Pharmaceuticals (ADIL) Sees Potential in FDA's New Approva - GuruFocus

Feb 23, 2026
pulisher
Feb 23, 2026

Portfolio Shifts: Can Adial Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Volume & Consistent Profit Alerts - baoquankhu1.vn

Feb 23, 2026
pulisher
Feb 21, 2026

Adial Pharmaceuticals at a Strategic Crossroads () - aktiencheck.de

Feb 21, 2026
pulisher
Feb 20, 2026

ADIL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 20, 2026
pulisher
Feb 20, 2026

Adial Pharmaceuticals to Present at Healthcare Conference - National Today

Feb 20, 2026
pulisher
Feb 19, 2026

Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight Alkermes, Teva Pharma, Biocorrx, Inc., Adial Pharma, ADDEX THERAPEUTICS - Mena FN

Feb 19, 2026
pulisher
Feb 19, 2026

Alcohol Use Disorder Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Alkermes, Teva Pharma, BioCorRx, Inc., Adial Pharma, ADDEX THERAPEUTICS - Barchart.com

Feb 19, 2026
pulisher
Feb 18, 2026

Fund Flows: Whats the beta of Adial Pharmaceuticals Inc stockCPI Data & Technical Entry and Exit Alerts - baoquankhu1.vn

Feb 18, 2026
pulisher
Feb 18, 2026

Armistice Capital, Steven Boyd report 9.99% stake in ADIL (NASDAQ: ADIL) - Stock Titan

Feb 18, 2026

Adial Pharmaceuticals Inc (ADIL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$99.29
price up icon 1.20%
$27.80
price up icon 0.00%
$52.37
price down icon 0.06%
$89.31
price down icon 0.77%
$144.00
price up icon 0.91%
biotechnology ONC
$282.72
price up icon 0.15%
자본화:     |  볼륨(24시간):